about
Sanfilippo syndrome: causes, consequences, and treatmentsFemale mucopolysaccharidosis IIIA mice exhibit hyperactivity and a reduced sense of danger in the open field testMolecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implicationsDevelopment of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type BLong-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series.An investigation of the middle and late behavioural phenotypes of Mucopolysaccharidosis Type-III.Assessment of sleep in children with mucopolysaccharidosis type III.Psychological health in adults with morquio syndrome.Melatonin supplementation for severe and intractable sleep disturbance in young people with genetically determined developmental disabilities: short review and commentaryActigraphic investigation of circadian rhythm functioning and activity levels in children with mucopolysaccharidosis type III (Sanfilippo syndrome)The Neurobehavioral Phenotype in Mucopolysaccharidosis Type IIIB: an Exploratory Study.A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS IIMucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder.Sleep problems in children with neurological disorders.Parents' experiences of living with, and caring for children, adolescents and young adults with Mucopolysaccharidosis (MPS).Natural history of Sanfilippo syndrome in Spain.Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders.Management of the behavioural manifestations of Hunter syndrome.Parental social support, coping strategies, resilience factors, stress, anxiety and depression levels in parents of children with MPS III (Sanfilippo syndrome) or children with intellectual disabilities (ID).Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome).A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II.Psychopharmacological treatment of behavioural problems in Sanfilippo syndrome.Symptoms of Autism Spectrum Disorder (ASD) in Individuals with Mucopolysaccharide Disease Type III (Sanfilippo Syndrome): A Systematic Review.Mortality in patients with Sanfilippo syndrome.Sleep disturbance in Sanfilippo syndrome: a parental questionnaire study.Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III.Health-Related Quality of Life in Patients with MPS II.Coping Strategies, Stress, and Support Needs in Caregivers of Children with Mucopolysaccharidosis.Social Functioning and Behaviour in Mucopolysaccharidosis IH [Hurlers Syndrome].Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey.Sleep disorders in Sanfilippo syndrome: a polygraphic study.MPS II: adaptive behavior of patients and impact on the family system.
P2860
Q26773200-1F9B4461-B25A-4F91-A506-7E0294DB8135Q27317299-A7AB2A7E-3C87-4CDF-94E9-41A684B2E209Q28201581-F95821D4-6F2A-4779-B669-D05F0EBA7441Q28512711-B5D3FCBD-B4A8-4B4A-B7BF-7EB2D162C24BQ34152598-720248EA-2A38-4D34-B46C-52C25B8C24DEQ35052627-83967C9D-ECE6-4F12-9B2A-1D5D924CF52FQ35087812-F55F0C4E-D860-4AC7-B606-9822E0157AD9Q35220728-3BFB60ED-D03B-4FB0-9AFD-1DFE422F0035Q35588990-7226257A-4605-4198-BD36-037F84F94783Q36071109-3EBB5717-E5CF-4ADB-ACFC-C59A7D0A35FDQ36602806-368D356C-BB75-4514-B4E8-4A66A8B59C48Q36799227-2B1EA92B-CA94-4F71-BDBE-53FE703F06FBQ36844479-CAD0D9D9-65E9-47E6-8DE9-D55FD7CDD1D9Q37139539-02FBF390-C377-426C-AE61-26AC5FC52D7BQ37325706-9A975EF1-E7F8-4D77-9EA5-D096D08D4850Q37428010-099A9D12-8621-480F-A953-E93D5D9E682FQ38079401-280100D1-DAC5-4845-AFA8-52EFDEBE1D24Q38696810-0A035091-1D7F-47F5-83D4-514E958142FFQ39297656-F16F148A-AFAD-43A7-90E0-837A6EB23FBDQ40763476-061E79A5-651D-406C-9C7F-FD500F1EB1B6Q41122864-CB8001D4-9DFB-492B-9242-D2AD29C74170Q41813572-FEA2EC09-0773-425F-A03D-4714B0F5CF81Q42373390-844668F5-98D6-428B-9510-FE4479CB4972Q42644024-C8EF043D-811E-4341-AC59-5A8557B3DB44Q43098901-56664BCC-FFE6-404A-A1D3-277DDCF9A640Q43292008-A03B0266-240E-4129-AE3F-E9CF549E4AE2Q45962203-BE960495-39EF-40E0-8F34-1BB92471575AQ47565886-6EAE1A9E-18C7-491F-BDC1-AB2B6F5B05D2Q47658381-382F9561-21EE-4F81-A422-1D23B200C510Q48070205-51698BB1-6D89-4BD8-A7D1-2F3FEDD9E7F0Q48640285-0BC51DF0-E9D5-4AB8-825B-D4FAFDF2618AQ50356355-8F22A375-5131-4255-9F90-00AEA2548A77
P2860
description
1995 nî lūn-bûn
@nan
1995 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Behaviour in mucopolysaccharide disorders.
@ast
Behaviour in mucopolysaccharide disorders.
@en
Behaviour in mucopolysaccharide disorders.
@nl
type
label
Behaviour in mucopolysaccharide disorders.
@ast
Behaviour in mucopolysaccharide disorders.
@en
Behaviour in mucopolysaccharide disorders.
@nl
prefLabel
Behaviour in mucopolysaccharide disorders.
@ast
Behaviour in mucopolysaccharide disorders.
@en
Behaviour in mucopolysaccharide disorders.
@nl
P2860
P356
P1476
Behaviour in mucopolysaccharide disorders.
@en
P2093
P2860
P356
10.1136/ADC.73.1.77
P407
P577
1995-07-01T00:00:00Z